3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors Improve Myocardial High-Energy Phosphate Metabolism in Men

Journal of Cardiovascular Magnetic Resonance

Volumn 5, Issue 4, 2003, Pages 595-602

  Schocke, Michael F H ^a   Martinek, Martin ^a   Kremser, Christian ^a   Wolf, Christian ^a   Steinboeck, Peter ^a   Lechleitner, Monika ^b   Jaschke, Werner ^a   Pachinger, Otmar ^a   Metzler, Bernhard ^a,b  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Hypercholeterolemia; Myocardium; Phosphorus 31 two dimensional chemical shift imaging; Statins

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; ECHOCARDIOGRAPHY; FAMILIAL HYPERCHOLESTEROLEMIA; HEART LEFT VENTRICLE; HEART MUSCLE; HIGH ENERGY PHOSPHATE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHATE METABOLISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; STRESS;

ADENOSINE TRIPHOSPHATE; ADULT; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL, LDL; ECHOCARDIOGRAPHY; EXERCISE TEST; HEART VENTRICLES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MAGNETIC RESONANCE IMAGING, CINE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MYOCARDIUM; PHOSPHATES; PHOSPHOCREATINE; PHOSPHORUS;

EID: 0242499349     PISSN: 10976647     EISSN: None     Source Type: Journal    
DOI: 10.1081/JCMR-120025234     Document Type: Article

References (23)

1. Datta, S. R., Brunet, A., Greenberg, M. E. (1999). Cellular survival: a play in three Akts. Genes Dev. 13:2905-2927.
2. Goldstein, J. L., Brown, M. S. (1990). Regulation of the mevalonate pathway. Nature 343:425-430.
3. Hall, A. (1998). Rho-GPTases and the actin cytoskeleton Science 279:509-514.
4. Hardy, C. J., Weiss, R. G., Bottomley, P. A., Gersenblith, G. (1991). Altered myocardial high energy phosphate metabolites in patients with dilated cardiomyopathy. Am. Heart J. 122:795-801.
5. Ikeda, U., Shimpo, M., Ikeda, M., Minota, S., Shimada, K. (2001). Lipophilic statins augment inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. J. Cardiovasc. Pharmacol. 38:69-77.
6. Kawabata, H., Ryomoto, T., Ishikawa, K. (2001). Role of cardiac ATP-sensitive K+ channels induced by HMG CoA reductase inhibitor in ischemic rabbit hearts. Hypertens. Res. 24:573-577.
7. Kureishi, Y., Luo, Z., Shiojima, I., Bialik, A., Fulton, D., Lefer, D. J., Sessa, W., Walsh, K. (2000). The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6:1004-1010.
8. Laufs, U., Liao, J. K. (2000). Targeting rho in cardiovascular disease. Circ. Res. 87:526-528.
9. Lefer, A. M., Scalia, R., Lefer, D. J. (2001). Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc. Res. 49:281-287.
10. Metzler, B., Schocke, M. F. H., Steinboeck, P., Wolf, C., Judmaier, W., Lechleitner, M., Lukas, P., Pachinger, O. (2002). Decreased high energy phosphate ratios in the myocardium of men with diabetes mellitus type I. J. Cardiovasc. Magn. Res. 4:493-502.
11. 31P-magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease: altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86:1810-1818.
12. Recchia, F. A., McConnell, P. I., Bernstein, R. D., Vogel, T. R., Xu, X., Hintse, T. H. (1998). Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ. Res. 83:969-979.
13. Rikitake, Y., Kawashima, S., Takeshita, S., Amashita, T., Azumi, H., Yasuhara, M., Nishi, H., Inoue, N., Yokoyama, M. (2001). Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol fed rabbits. Atherosclerosis 154:87-96.
14. Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N. Engl. J. Med. 335:1001-1009.
15. Schocke, M. F. H., Metzler, B., Wolf, C., Steinboeck, P., Kremser, C., Pachinger, O., Jaschke, W., Lukas, P. (2003). Impact of aging on cardiac high-energy phosphate metabolism determined by phosphorus-31 2-dimensional chemical shift imaging (31P 2D CSI). Magn. Reson. Imaging 24:553-559.
16. Sheffield, L. T. (1988). Exercise stress testing. In: Braunwald, E., Ed. Heart Disease. A Textbook of Cardiovascular Medicine. Philadelphia, PA: WB Saunders Co, pp. 223-286.
17. Shen, W., Hintze, T. H., Wolin, M. S. (1995). Nitric oxide: an important signalling mechanism between vascular endothelium and parenchymal cells in the regulation of oxygen consumption. Circulation 92:1086-1095.
18. Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., MacFarlane, P. W., McKillop, J. H., Packard, C. J. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N. Engl. J. Med. 16:1301-1307
19. Takemoto, M., Liao, J. K. (2001). Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibiors. Arterioscler Thromb. Vasc. Biol. 21:1712-1719.
20. Tamai, O., Matsuoka, H., Itabe, H., Wada, Y., Kohno, K., Imaizumi, T. (1997). Single LDL apharesis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 95:76-82.
21. The Scandinavian Simvastatin Survival Study (4S). (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344:1383-1389.
22. Tsao, P. S., Cooke, J. P. (1998). Endothelial alterations in hypercholesterolemia: more than simply vasodilator dysfunction. J. Cardiovasc. Pharm. 32:48-53.
23. Weiss, R. G., Bottomley, P. A., Hardy, C. J., Gerstenblith, G. (1990). Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. N. Engl. J. Med. 323:1593-1600.